Mats Wahlstrom is Director at Coherus Oncology, Inc. (CHRS). They have made 11 open-market trades across 2 companies since 2015, most recently 2026-06-05.
CIK 0001459154
3 open-market purchases totalling $222K since 2016, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TLSI | 147,555 | $539K |
| CHRS | 30,000 | $30K |
| HGRD | 33,500 | — |
| Total | $569K |
Shares reported on the most recent Form 4, priced at the 2026-06-09 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TLSI | BUY | 2026-05-15 | 2026-05-18 | $2.53 | $152K | +0.4% | +14.8% | +55.1% |
| CHRS | SELL | 2025-05-23 | 2025-05-28 | $0.74 | $148K | +6.9% | -7.0% | +41.4% |
| TLSI | BUY | 2024-11-22 | 2024-11-25 | $4.55 | $23K | +15.4% | +21.7% | +34.4% |
| TLSI | BUY | 2024-11-20 | 2024-11-22 | $4.39 | $47K | -10.8% | -11.2% | +23.0% |
| CHRS | SELL | 2020-06-17 | 2020-06-19 | $17.15 | $6.9M | +7.4% | +10.6% | +12.2% |
| CHRS | SELL | 2020-03-03 | 2020-03-05 | $20.12 | $4.8M | -31.9% | -18.9% | -4.2% |
| CHRS | SELL | 2016-12-07 | 2016-12-09 | $27.52 | $2.9M | -0.5% | -1.4% | -16.4% |
| CHRS | SELL | 2015-08-18 | 2016-05-26 | $33.50 | $213K | +0.1% | -21.6% | +60.7% |
| CHRS | SELL | 2015-08-18 | 2015-08-20 | $33.50 | $213K | -37.4% | -6.3% | -6.3% |
| CHRS | SELL | 2015-08-17 | 2015-08-19 | $33.91 | $272K | -37.4% | -6.3% | -6.3% |
| CHRS | SELL | 2015-08-14 | 2015-08-18 | $34.24 | $4.0M | -37.4% | -6.3% | -6.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.